drugset / Trial / NCT01178528

Heart Rate Reduction in Heart Failure

NCT01178528

Phase 3 Completed 121 enrolled IRCCS San Raffaele
RandomizedParallel-groupDouble-blindTreatment

Summary

Patients with heart failure (HF) have a limited exercise tolerance,few pharmacological interventions have been proven effective in improving exercise capacity. At the presence there i conflicting evidence on the effectiveness of beta-blockers on exercise capacity. Ivabradine has been shown to improve prognosis in patients with ischemic heart disease, left ventricular dysfunction and heart rate \> 70 bpm. The association of ivabradine and atenolol has been proven effective in increasing exercise tolerance in patients with ischemic heart disease. Aim of the present study is to evaluate the effect of heart rate reduction with ivabradine, carvedilol or their combination in patients with heart failure of ischemic origin.

Timeline

Start
2009-09
Primary completion
2010-06
Completion
2010-10

Drugs

EvaluationDrugModalityDoseRoute
Subject Carvedilol Other / unclassified 12.5 mg
Subject Carvedilol Other / unclassified 25 mg
Subject Ivabradine Small molecule 5 mg
Subject Ivabradine Small molecule 7.5 mg

Indications